Department of Diabetes and Metabolism, Tohoku University Hospital, 2-1 Seiryo, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Division of Hematopathology, Tohoku University Hospital, Sendai, Aoba-ku, Japan.
BMC Endocr Disord. 2020 Sep 29;20(1):148. doi: 10.1186/s12902-020-00624-2.
A high-molecular-weight form of insulin-like growth factor-2 (IGF-2), known as "big" IGF-2, is occasionally produced by various tumor types, leading to hypoglycemia. Although solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm, it has been estimated that 4-6% of SFT patients develop hypoglycemia due to circulating big IGF-2. The mean time elapsed from tumor detection until the onset of hypoglycemia is reportedly less than one year (8.5 ± 1.9 months).
A 68-year-old man was hospitalized for exacerbation of recurring hypoglycemic episodes. He had been diagnosed with an SFT 17 years before the onset of hypoglycemia, and the SFT had already been very large at that time. The tumor, which was non-resectable and refractory to chemotherapies, had slowly increased in size since the initial diagnosis. Half a year before the hypoglycemic episodes manifested, another tumor, adjacent to the left kidney, was newly identified. Fluorodeoxyglucose positron emission tomography-computed tomography scanning, revealed the left peri-renal tumor to show much higher fluorodeoxyglucose uptake than the preexisting SFT, suggesting that it was unlikely to be a metastasis from the SFT. Abundant serum big IGF-2 was detected by western immunoblot analysis, indicating it to be the cause of the hypoglycemia. Since the 17 years between SFT detection and the onset of IGF-2-induced hypoglycemia was an extremely long period as compared with those in previous reports, we initially suspected that the new, peri-renal tumor had produced big IGF-2, but transcatheter arterial embolization of its feeding arteries did not suppress hypoglycemia. Notably, by measuring the tumor volume doubling time, the peri-renal tumor growth was shown to be markedly accelerated in parallel with exacerbation of the hypoglycemia. The patient died of heart failure 21 months after the onset of hypoglycemia. Unexpectedly, autopsy revealed that big IGF-2 had been produced only by the preexisting SFT, not the peri-renal tumor, and that the peri-renal tumor was a dedifferentiated liposarcoma.
We should keep in mind that even a long-inactive SFT can undergo transformation to produce big IGF-2, which then acts on both insulin and IGF-1 receptors, possibly leading to both hypoglycemia and the development/growth of another tumor, respectively.
胰岛素样生长因子-2(IGF-2)的高分子量形式,即“大”IGF-2,偶尔由各种肿瘤类型产生,导致低血糖。尽管孤立性纤维瘤(SFT)是一种罕见的间叶性肿瘤,但据估计,4-6%的 SFT 患者因循环中的大 IGF-2 而发生低血糖。据报道,从肿瘤检测到低血糖发作的平均时间不到一年(8.5±1.9 个月)。
一名 68 岁男性因反复发作的低血糖发作加重而住院。他在低血糖发作前 17 年被诊断出患有 SFT,当时 SFT 已经非常大。由于无法切除且对化疗有抗药性,自最初诊断以来,肿瘤一直在缓慢增大。在低血糖发作前半年,新发现一个毗邻左肾的肿瘤。氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描显示左肾周肿瘤的氟脱氧葡萄糖摄取量明显高于先前的 SFT,提示不太可能是 SFT 的转移。通过 Western 免疫印迹分析检测到大量血清大 IGF-2,表明这是低血糖的原因。由于 SFT 检测到 IGF-2 诱导的低血糖发作之间的 17 年时间与之前的报告相比非常长,我们最初怀疑新的肾周肿瘤产生了大 IGF-2,但对其供血动脉进行经导管动脉栓塞并没有抑制低血糖。值得注意的是,通过测量肿瘤倍增时间,显示肾周肿瘤的生长与低血糖恶化呈平行加速。低血糖发作 21 个月后,患者死于心力衰竭。出乎意料的是,尸检显示,只有先前存在的 SFT 产生了大 IGF-2,而不是肾周肿瘤,肾周肿瘤是去分化脂肪肉瘤。
我们应该记住,即使是长期不活跃的 SFT 也可能发生转化,产生大 IGF-2,然后作用于胰岛素和 IGF-1 受体,可能导致低血糖和另一个肿瘤的发展/生长。